Puja P Khanna, MD, MPH

 Puja Khanna
Clinical Professor of Internal Medicine and Service Chief
Internal Medicine
Medical School
[email protected]
Available to mentor
Puja P Khanna, MD, MPH
Puja Khanna
Clinical Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation

    Recent Publications

     See All Publications
    • Presentation
      Rheumatology for the Primary Care Physician
      Khanna P. 2026 Mar 27;
    • Presentation
      Rheumatology for the Primary Care Physician
      Khanna P. 2026 Mar 27;
    • Journal Article
      The Rheumatologist as the Agent of Change: Utility of Guidelines in the Management of Gout
      Khanna PP. Journal of Rheumatology, 2025 Jan 1; 52 (1): 4 - 5. DOI:10.3899/jrheum.2024-0957
      PMID: 39406406
    • Proceeding / Abstract / Poster
      Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
      Khanna P. 2024 Nov 17;
    • Proceeding / Abstract / Poster
      Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
      Khanna P, Strand V. 2024 Nov 17;
    • Proceeding / Abstract / Poster
      Inpatient Discontinuation of Allopurinol - A Qualitative Improvement (QI) Initiative
      Khanna P, Al-Dulaijan B, Tancer S. 2024 Nov 17;
    • Journal Article
      Efficacy and Safety of SEL-212 in Patients with Refractory Gout and CKD: A Post Hoc Analysis from the Two Phase 3 DISSOLVE Studies
      Khanna P, Johnson RJ, Azeem R, Falk A, Desai B, Santin-Janin H, Baraf H, Kivitz AJ. Journal of the American Society of Nephrology, 2024 Oct 30; 35 (10S): 10.1681/asn.202457c52mh7 DOI:10.1681/asn.202457c52mh7
    • Journal Article
      POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS
      Baraf HSB, Khanna P, Patel A, Singhal A, Sobierska J, Santin-Janin H, Azeem R, Dehaan W, Traber P, Kivitz A. Annals of the Rheumatic Diseases, 2024 Jun 12; 83: 408 - 409. DOI:10.1136/annrheumdis-2024-eular.2832